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Dear Editors,
It is really very exciting to know that another Brazilian 
group is working with molecular investigation in the field of 
psychiatric genetics.1 When we decided to write a paper about 
the particularities, advantages and difficulties of conducting 
psychiatric genetic studies in the Brazilian population, we were 
aware of the possible biases of a narrative review.2 However, that 
kind of approach seemed to be a more appropriate method in 
terms of our proposal because we believe that, by describing the 
history, development, and management of psychiatric genetic 
investigations in Brazil, we would be contemplating several 
contextual, cultural and political aspects and integrating different 
and independent fields of research in order to acquire a wider and 
multidisciplinary view of the subject at hand.
There is also another important point raised by Salum et al.1 
that needs to be addressed. Differently from what they claim, the 
use of “more homogenous samples like the Caucasians” does not 
“avoid stratification” in association studies on complex disorders 
such as neuropsychiatric disorders.2
Nowadays, it is well known that even when studying samples 
from a specific continental population such as the European, 
ethnic stratification can produce false associations at markers 
whose frequency differs across subpopulations.3 For example, in 
a recent whole genome association study of rheumatoid arthritis 
in European Americans, markers in the LCT and IRF4 genes 
could have been falsely implicated as being associated with the 
disease had no control method been applied to for the population’s 
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stratification.4 Certain studies have suggested that angiotensin I 
converting enzyme (ACE) gene polymorphism is associated with 
an increased risk of late onset Alzheimer’s disease. However, when 
studying this, Panza et al. have found inconsistent findings within 
European studies.5 Interestingly, there is a statistically significant 
decreasing trend of the ACE*I/*D genotype frequency from 
northern to southern regions of Europe, which may contribute to 
explain the different patterns of associations found between such 
polymorphism and Alzheimer’s disease across Europe.5 Recent 
investigations have suggested that genetic association studies in 
European Americans should use ancestry informative markers for 
examining north-south, Ashkenazi Jewish, and Irish ancestry.3
Several statistical methods have been developed to control 
for population stratification. Some studies have proposed that, 
considering that a small number of candidate markers may not 
be sufficiently informative and that genotyping a large number 
of markers can be expensive, the use of microarrays for ancestry 
estimation and correction has to be considered as a valuable tool 
when attempting to identify genes for complex traits through 
association studies involving European and European American 
populations. However, while studying subjects from European 
ancestry in Rio Grande do Sul, which is also Mr. Salum and his 
colleagues´ home state, a group of Brazilian researchers found a 
hidden ethnic admixture and proposed an interesting and cheap 
genomic control that can be used at the individual level, thus 
correcting for stratification by removing certain individuals from 
the sample without losing any statistical power due to statistical 
corrections.6
Quirino Cordeiro, Homero Vallada
Program of Genetics and Pharmacogenetics, Department 
and Institute of Psychiatry, Universidade de São Paulo (USP) 
Medical School, São Paulo (SP), Brazil 
Bruno Rezende Souza, Humberto Correa, 
Marco Aurélio Romano-Silva
Department of Mental Health, Medical School, 
Universidade Federal de Minas Gerais (UFMG), 
Belo Horizonte (MG), Brazil 
Camila Guindalini
Interdisciplinary Laboratory of Clinical Neuroscience, 
Department of Psychiatry, Universidade Federal de São Paulo 
(UNIFESP), São Paulo (SP), Brazil 
Mara Helena Hutz
Department of Genetics, Universidade Federal do Rio 
Grande do Sul (UFRGS), Porto Alegre (RS), Brazil 
Cartas aos Editores
94 • Revista Brasileira de Psiquiatria • vol 32 • nº 1 • mar2010
References
1. Salum GA, Blaya C, Segal J, Manfro GG, Leistner-Segal S. Emerging research 
groups in Brazilian psychiatric genetic studies. Rev Bras Psiquiatr. In 
press 2009.
2. Cordeiro Q, Souza BR, Correa H, Guindalini C, Hutz MH, Vallada H, Romano-
Silva MA. A review of psychiatric genetics research in the Brazilian 
population. Rev Bras Psiquiatr. 2009;31(2):154-62.
3. Seldin MF, Price AL. Application of ancestry informative markers 
to association studies in European Americans. PLoS Genet. 
2008;4(1):e5.
4. Tian C, Plenge RM, Ransom M, Lee A, Villoslada P, Selmi C, Klareskog 
L, Pulver AE, Gregersen PK, Seldin MF. Analysis and application of 
European genetic substructure using 300K SNP information. PLoS 
Genet. 2008;4(1):e4. 
5. Panza F, Solfrizzi V, D’Introno A, Colacicco AM, Capurso C, Capurso A, 
Kehoe PG. Shifts in angotensin I converting enzyme insertion allele 
frequency across Europe: implications for Alzheimer’s disease risk. J 
Neurol Neurosurg Phychiatry. 2003;74(8):1159-61.
6. Zembrzuski VM, Callegari-Jacques SM, Hutz MH. Application of an African 
Ancestry Index as a genomic control approach in a Brazilian population. 
Ann Hum Genet. 2006;70(6):822-8.
Treatment of apathy in 
Alzheimer’s disease with 
transdermal rivastigmine: 
report of three cases
Tratamento da apatia na  
doença de Alzheimer com 
rivastigmina transdérmica: 
relato de três casos
Dear Editor,
Apathy in Alzheimer’s disease is one of the most difficult 
behavioral and psychological symptoms to treat. Anticholinesterasic 
drugs, dopaminergic agonists, and psychostimulants are treatment 
alternatives based on studies with contradictory results.1 The use 
of transdermal rivastigmine has not been sufficiently studied 
in clinical trials, especially regarding the treatment of apathy. 
We report below 3 cases of dementia and apathy treated with 
transdermal rivastigmine, with behavioral symptoms analysis, 
cognitive testing and outcome measurement in the first, second, 
third and sixth months.
Case reports: Three female patients were evaluated – MO (81 
years old), ECN (74 years old) and DM (84 years old) – all of 
them meeting the criteria for Alzheimer’s Disease (based on DSM-
IV) and for apathy (based on the following criteria proposed 
by Robert P, 2009:2 1) the core feature of apathy, diminished 
motivation, must be present for at least four weeks; 2) two of the 
three dimensions of apathy (reduced goal-directed behaviour, goal-
directed cognitive activity, and emotions) must also be present; 3) 
there should be identifiable functional impairments attributable 
to apathy; 4) exclusion criteria are specified to exclude symptoms 
and states that mimic apathy. After the diagnosis of Alzheimer’s 
disease, the patients were treated with transdermal rivastigmine 
(4.6mg in the first month and 9.5mg after the second month). The 
improvement of apathy was observed after the introductions of 
anticholinesterasic treatment. The three cases are presented below:
1) DM presented at first meeting with: Mini Mental State 
Examination (MMSE) of 15/30, poor verbal contact, walking 
impairment, loss of manual abilities, and social isolation. After 
two months of treatment, the patient started to interact during 
the examination, returned to her manual and social activities, 
improved her walking balance and presented a MMSE of 21/30. 
After six months, the improvements were maintained.
2) ECN presented at first meeting with: MMSE of 20/30, 
difficulties in verbal contact, loss of instrumental activities of daily 
living (iADL), and social isolation. After two months of treatment, 
the patient returned with great improvement in verbal contact, 
returned to her iADL and presented a MMSE of 22/30. After six 
months, the improvements were maintained.
3) MO presented at first meeting with: MMSE of 13/30, poor 
verbal contact, loss of iADL and interruption of her morning 
exercise (walking). After two months of treatment, the patient 
was more collaborative, showed iADL improvement, returned 
to her physical activity and presented an MMSE of 10/30. The 
improvements were maintained after 6 months.
Discussion: Apathy is the most common neuropsychiatric 
syndrome in Alzheimer’s disease, affecting 30 to 60% of 
patients.1,2 Its pharmacologic therapy is based on three strategies: 
psychostimulants, dopaminergic agonists and anticholinesterasic 
drugs.1 
Despite being first tested and developed for the improvement 
of cognition in Alzheimer’s disease, anticholinesterasic drugs 
showed many benefits in the treatment of behavioral and 
psychological symptoms related to dementia, including apathy. 
Although systematic reviews point to a lack of well-designed 
studies concerning this issue, anticholinesterasic drugs remain 
as an appropriate therapy for apathy.3,4 The new presentation 
of transdermal rivastigmine has been studied as an option with 
fewer adverse effects (nausea and vomiting) when compared to 
other oral anticholinesterasic drugs,5 but no studies concerning 
their use in behavioral symptoms have been  conducted. In the 
cases reported above, there was a surprising improvement in 
the apathy of all patients, regardless of the changes in cognitive 
function. This finding brings new perspectives for the conduction 
of future randomized and double-blind studies evaluating the use 
of transdermal rivastigmine.
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